Bonus BioGroup Ltd. (BBIXF)
USD 0.02
(0.0%)
USD 0.02
(0.0%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -28.13 Million ILS | -3.73% |
| 2022 | -35.6 Million ILS | 59.54% |
| 2021 | -63.25 Million ILS | -264.56% |
| 2020 | -18.37 Million ILS | 8.16% |
| 2019 | -19.83 Million ILS | -10.2% |
| 2018 | -18.25 Million ILS | 8.98% |
| 2017 | -19.96 Million ILS | -29.37% |
| 2016 | -15.55 Million ILS | -19.56% |
| 2015 | -12.9 Million ILS | -20.18% |
| 2014 | -10.74 Million ILS | -12.75% |
| 2013 | -9.52 Million ILS | 47.12% |
| 2012 | -18.01 Million ILS | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -6.15 Million ILS | 12.46% |
| 2024 Q1 | -7.02 Million ILS | -6.04% |
| 2023 Q1 | -6.71 Million ILS | 60.43% |
| 2023 Q4 | -6.62 Million ILS | -14.2% |
| 2023 Q3 | -5.8 Million ILS | -1.06% |
| 2023 FY | - ILS | -3.73% |
| 2023 Q2 | -5.74 Million ILS | 14.56% |
| 2022 Q3 | -7.27 Million ILS | -92.97% |
| 2022 Q1 | -6.53 Million ILS | 80.75% |
| 2022 Q2 | -3.77 Million ILS | 42.28% |
| 2022 FY | - ILS | 59.54% |
| 2022 Q4 | -16.97 Million ILS | -133.35% |
| 2021 Q3 | -9.87 Million ILS | -24.87% |
| 2021 Q4 | -33.93 Million ILS | -243.75% |
| 2021 FY | - ILS | -264.56% |
| 2021 Q1 | -35.27 Million ILS | -344.13% |
| 2021 Q2 | -7.9 Million ILS | 77.59% |
| 2020 Q2 | -3.89 Million ILS | 7.82% |
| 2020 Q1 | -4.22 Million ILS | 18.47% |
| 2020 Q3 | -2.76 Million ILS | 28.94% |
| 2020 FY | - ILS | 8.16% |
| 2020 Q4 | -7.94 Million ILS | -187.27% |
| 2019 Q3 | -4.29 Million ILS | -8.74% |
| 2019 Q1 | -7.08 Million ILS | -38.59% |
| 2019 FY | - ILS | -10.2% |
| 2019 Q4 | -5.17 Million ILS | -20.62% |
| 2019 Q2 | -3.94 Million ILS | 44.32% |
| 2018 Q1 | -4.98 Million ILS | -37.14% |
| 2018 Q4 | -5.11 Million ILS | -23.02% |
| 2018 FY | - ILS | 8.98% |
| 2018 Q3 | -4.15 Million ILS | -6.18% |
| 2018 Q2 | -3.91 Million ILS | 21.44% |
| 2017 FY | - ILS | -29.37% |
| 2017 Q3 | -9.31 Million ILS | -162.65% |
| 2017 Q2 | -3.54 Million ILS | -1.99% |
| 2017 Q4 | -3.63 Million ILS | 60.96% |
| 2017 Q1 | -3.47 Million ILS | -7.22% |
| 2016 Q1 | -3.05 Million ILS | 28.46% |
| 2016 FY | - ILS | -19.56% |
| 2016 Q2 | -3.06 Million ILS | -0.2% |
| 2016 Q4 | -3.24 Million ILS | 47.65% |
| 2016 Q3 | -6.19 Million ILS | -102.25% |
| 2015 Q3 | -3.36 Million ILS | -19.87% |
| 2015 Q2 | -2.8 Million ILS | -13.3% |
| 2015 Q1 | -2.47 Million ILS | 10.56% |
| 2015 FY | - ILS | -20.18% |
| 2015 Q4 | -4.27 Million ILS | -27.14% |
| 2014 Q2 | -2.85 Million ILS | 6.92% |
| 2014 FY | - ILS | -12.75% |
| 2014 Q1 | -3.06 Million ILS | 2.51% |
| 2014 Q3 | -2.05 Million ILS | 27.81% |
| 2014 Q4 | -2.76 Million ILS | -34.34% |
| 2013 FY | - ILS | 47.12% |
| 2013 Q1 | -2.12 Million ILS | 0.0% |
| 2013 Q2 | -1.86 Million ILS | 12.16% |
| 2013 Q3 | -2.39 Million ILS | -28.77% |
| 2013 Q4 | -3.14 Million ILS | -31.01% |
| 2012 FY | - ILS | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | -71.03 Million USD | 60.389% |
| Nanobac Pharmaceuticals, Incorporated | -5.92 Million USD | -374.59% |
| SQZ Biotechnologies Company | -64.14 Million USD | 56.131% |
| Evofem Biosciences, Inc. | -17.37 Million USD | -61.992% |
| Santhera Pharmaceuticals Holding AG | 94.03 Million USD | 129.922% |
| Mesoblast Limited | -62.38 Million USD | 54.9% |
| Propanc Biopharma, Inc. | -1.53 Million USD | -1731.843% |
| Genus plc | 73.7 Million USD | 138.179% |
| VioQuest Pharmaceuticals, Inc. | -6.61 Million USD | -325.591% |
| CNBX Pharmaceuticals Inc. | -3.54 Million USD | -693.291% |
| Marizyme, Inc. | -34.28 Million USD | 17.921% |
| ContraFect Corporation | -64.99 Million USD | 56.71% |
| Nymox Pharmaceutical Corporation | -8.77 Million USD | -220.771% |
| PsyBio Therapeutics Corp. | -4.52 Million USD | -521.67% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | -1907.265% |
| Intellipharmaceutics International Inc. | -2.64 Million USD | -964.041% |
| AXIM Biotechnologies, Inc. | -2.32 Million USD | -1110.851% |
| MultiCell Technologies, Inc. | -518.04 Thousand USD | -5331.564% |
| Accustem Sciences Inc. | -3.74 Million USD | -651.064% |
| RVL Pharmaceuticals plc | -48.22 Million USD | 41.655% |
| EV Biologics, Inc. | -1.26 Million USD | -2120.605% |
| Q BioMed Inc. | -617.62 Thousand USD | -4455.817% |
| Emmaus Life Sciences, Inc. | 3.57 Million USD | 887.738% |
| Neon Bloom, Inc. | -632.4 Thousand USD | -4349.357% |
| Mosaic ImmunoEngineering Inc. | -2.28 Million USD | -1131.698% |
| Biomind Labs Inc. | -1.03 Million USD | -2619.833% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Pharming Group N.V. | 9.87 Million USD | 384.884% |
| Oncotelic Therapeutics, Inc. | -7.16 Million USD | -292.919% |
| Skye Bioscience, Inc. | -13.54 Million USD | -107.698% |
| Therapeutic Solutions International, Inc. | -1.48 Million USD | -1791.742% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | -112452.0% |
| Arch Therapeutics, Inc. | -3.88 Million USD | -624.4% |
| IMV Inc. | -35.52 Million USD | 20.79% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | -77.306% |
| Curative Biotechnology, Inc. | -2.5 Million USD | -1024.637% |
| GB Sciences, Inc. | -1.41 Million USD | -1881.71% |
| Alpha Cognition Inc. | -9.7 Million USD | -189.915% |
| HST Global, Inc. | -5303.00 USD | -530505.318% |
| CSL Limited | 4.78 Billion USD | 100.588% |
| Halberd Corporation | -74.27 Thousand USD | -37781.501% |
| Enzolytics Inc. | -2.12 Million USD | -1225.995% |
| Resverlogix Corp. | -11.74 Million USD | -139.635% |
| Affymax, Inc. | -14.29 Million USD | -96.838% |
| SYBLEU INC | -141.57 Thousand USD | -19775.539% |
| Nuo Therapeutics, Inc. | -3.06 Million USD | -818.637% |
| argenx SE | -216.02 Million USD | 86.975% |
| MetaStat, Inc. | - USD | Infinity% |
| Northwest Biotherapeutics, Inc. | -55.33 Million USD | 49.153% |
| Enzon Pharmaceuticals, Inc. | 1.21 Million USD | 2412.079% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| RespireRx Pharmaceuticals Inc. | -1.49 Million USD | -1777.236% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | 378.84 Thousand USD | 7527.332% |
| AVAX Technologies, Inc. | -6.11 Million USD | -360.325% |
| Zenith Capital Corp. | -8.6 Million USD | -226.958% |
| Genscript Biotech Corporation | -248.71 Million USD | 88.687% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -161417.709% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -2.44 Million USD | -1050.151% |
| WPD Pharmaceuticals Inc. | -176.02 Thousand USD | -15885.287% |
| American Oriental Bioengineering, Inc. | -39.63 Million USD | 29.011% |
| Provectus Biopharmaceuticals, Inc. | -2.89 Million USD | -872.85% |
| Adynxx, Inc. | - USD | Infinity% |
| Helix BioMedix, Inc. | -1.04 Million USD | -2589.255% |
| GlobeStar Therapeutics Corporation | 6724.00 USD | 418571.148% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -1.74 Million USD | -1507.887% |
| Cotinga Pharmaceuticals Inc. | -1.92 Million USD | -1364.826% |
| BioStem Technologies, Inc. | -7.55 Million USD | -272.509% |
| ONE Bio Corp. | 13.61 Million USD | 306.699% |
| Reve Technologies, Inc. | -181.08 Thousand USD | -15438.302% |
| Burzynski Research Institute, Inc. | - USD | Infinity% |
| Wesana Health Holdings Inc. | -2.05 Million USD | -1267.914% |
| Agentix Corp. | -1.37 Million USD | -1951.239% |
| LadRx Corporation | 412.28 Thousand USD | 6924.924% |
| Cell Source, Inc. | -4.27 Million USD | -558.58% |
| ProtoKinetix, Incorporated | -367.22 Thousand USD | -7562.416% |
| Regen BioPharma, Inc. | 1.46 Million USD | 2019.43% |
| Regen BioPharma, Inc. | -936.94 Thousand USD | -2903.152% |
| NovAccess Global Inc. | -1.03 Million USD | -2619.181% |
| Endonovo Therapeutics, Inc. | 8.85 Million USD | 417.807% |
| Itoco Inc. | -1.86 Million USD | -1405.515% |
| Rasna Therapeutics, Inc. | -379.62 Thousand USD | -7312.149% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | -2421.326% |
| Kadimastem Ltd | -2.62 Million USD | -972.177% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Institute of Biomedical Research Corp. | -239.15 Thousand USD | -11665.837% |
| CytoDyn Inc. | -18.02 Million USD | -56.071% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -79.02 Thousand USD | -35504.651% |
| Mobile Lads Corp. | -2.24 Million USD | -1155.511% |
| NanoSphere Health Sciences Inc. | -12.22 Thousand USD | -229992.403% |
| Qrons Inc. | -40.08 Thousand USD | -70102.839% |
| Alseres Pharmaceuticals, Inc. | -485.67 Thousand USD | -5693.55% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| Nascent Biotech, Inc. | 527.43 Thousand USD | 5434.896% |
| Rebus Holdings, Inc. | -951 Thousand USD | -2858.78% |
| ImmunoCellular Therapeutics, Ltd. | -1.06 Million USD | -2549.504% |
| International Stem Cell Corporation | 202 Thousand USD | 14029.703% |
| Bioxytran, Inc. | -3.82 Million USD | -636.569% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -53353.647% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.46 Million USD | -1042.924% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -35.86 Million USD | 21.553% |
| Adhera Therapeutics, Inc. | - USD | Infinity% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -45 Thousand USD | -62428.889% |
| Innovation Pharmaceuticals Inc. | -2.73 Million USD | -927.684% |
| Neutra Corp. | -181.24 Thousand USD | -15424.671% |
| Windtree Therapeutics, Inc. | -20.15 Million USD | -39.58% |
| PureTech Health plc | -11.62 Million USD | -142.006% |
| Coeptis Therapeutics, Inc. | -20.15 Million USD | -39.59% |
| IXICO plc | -707 Thousand USD | -3879.915% |
| IntelGenx Technologies Corp. | -7.68 Million USD | -266.142% |
| Gelesis Holdings, Inc. | -48.34 Million USD | 41.799% |
| CSL Limited | 4.73 Billion USD | 100.595% |
| Cellectis S.A. | -92.63 Million USD | 69.625% |